Need To Know: The Consensus Just Cut Its AbCellera Biologics Inc. (NASDAQ:ABCL) Estimates For 2024 [Yahoo! Finance]
AbCellera Biologics Inc. - Common Shares (ABCL)
Company Research
Source: Yahoo! Finance
their statutory estimates that might leave shareholders a little shell-shocked. Revenue estimates were cut sharply as analysts signalled a weaker outlook - perhaps a sign that investors should temper their expectations as well. After the downgrade, the nine analysts covering AbCellera Biologics are now predicting revenues of US$34m in 2024. If met, this would reflect an okay 3.1% improvement in sales compared to the last 12 months. Per-share losses are expected to see a sharp uptick, reaching US$0.57. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$42m and losses of US$0.57 per share in 2024. So there's definitely been a change in sentiment in this update, with the analysts administering a substantial haircut to this year's revenue estimates, while at the same time holding losses per share steady. See our latest analysis for AbCellera Biologics the analysts have cut their price target 7.0% to US$13.38 per share, signalling that the declining r
Show less
Read more
Impact Snapshot
Event Time:
ABCL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABCL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABCL alerts
High impacting AbCellera Biologics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ABCL
News
- Carl Hansen Buys Handful Of Shares In AbCellera Biologics [Yahoo! Finance]Yahoo! Finance
- AbCellera to Present at Upcoming Investor Conferences in SeptemberBusiness Wire
- AbCellera Biologics Inc. (ABCL): A Top Contender Among Canada's Best Penny Stocks in 2024 [Yahoo! Finance]Yahoo! Finance
- Eli Lilly doubles down on Oblique partnership for antibody generation [Yahoo! Finance]Yahoo! Finance
- AbCellera Biologics Inc. (NASDAQ: ABCL) was downgraded by analysts at Benchmark Co. from a "buy" rating to a "hold" rating.MarketBeat
ABCL
Earnings
- 8/6/24 - Beat
ABCL
Sec Filings
- 8/29/24 - Form 4
- 8/6/24 - Form 10-Q
- 8/6/24 - Form 8-K
- ABCL's page on the SEC website